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Background: The prognostic importance of extramedullary involvement in patients with Waldenström
macroglobulinemia (WM) at diagnosis and treatment options for these patients has not been well evaluated.
In this study, we investigated the clinical manifestations, biological features, and effect of first-line therapy on the
outcome of WM patients diagnosed with extramedullary involvement (EMWM) vs those with only bone marrow
involvement (BMWM).
Methods: We analyzed the clinical data of 312 WM patients diagnosed with EMWM (n = 106) and BMWM
(n = 206) at The University of Texas MD Anderson Cancer Center from 1994 to 2014. EMWM was confirmed by
biopsy, positron emission tomography–computed tomography, or magnetic resonance imaging, and clinical
laboratory analyses.
Results: Characteristics associated with EMWM were male sex (P = 0.027), age younger than 65 years (P = 0.048),
presence of B symptoms (P < 0.001), high serum beta-2 macroglobulin (P < 0.001) level, low serum albumin level
(P = 0.036), and cytogenetic abnormalities (P = 0.010). Kaplan-Meier survival analysis results showed that EMWM
patients had a significantly shorter median overall survival (P < 0.001) and progression-free survival (PFS) (P < 0.001) than
did BMWM patients. Chemotherapy combined with targeted therapy improved PFS for BMWM patients (P = 0.004) but
not for EMWM patients. Additionally, initial treatment with rituximab significantly improved the PFS of BMWM patients
(P = 0.012) but had no effect on EMWM patients. However, EMWM patients treated with nucleoside analogs attained a
better PFS than those who did not (P = 0.021).
Conclusions: We show that extramedullary involvement at diagnosis is an adverse prognostic factor in WM patients
and that first-line therapy with nucleoside analogs improved PFS for patients with EMWM. The study provides unique
clinical and treatment observations in subtypes of WM patients.
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Since the initial description of Waldenström macroglobu-
linemia (WM) in 1944, there have been great advances in
the definition and our understanding of this disease [1].
Waldenström macroglobulinemia, characterized by infil-
tration of the bone marrow (BM) with B-lymphocytes,
lymphoplasmacytic cells, and plasma cells, along with de-
tectable serum monoclonal immunoglobulin M (IgM) of
any level, is also considered to be a subset, albeit a very
large subset, of lymphoplasmacytic lymphoma (LPL) [2].
Approximately 1000–1500 patients are diagnosed with
WM per year in the United States [3].
Most of the patients with WM at time of initial diagno-
sis are with disease restricted to the bone marrow. They
may have symptoms including anemia, other peripheral
cytopenias, less commonly hyperviscosity syndrome, and
paraprotein deposition in various tissues, as a result of
tumor cell secretion of paraprotein. They also can have
symptoms associated with tumor cells infiltrating lymph
nodes or other organs. Although WM is classified as a
non-Hodgkin lymphoma, WM involves lymph nodes or
other organs less often than other types of non-Hodgkin
lymphoma [4]. The unique features of WM are captured
in its own, distinct staging system (the International
Staging System for WM [ISSWM]), which includes:
age, hemoglobin (Hb), platelet count (PLT), beta-2 mi-
croglobulin level (β2-MG), and IgM level [5]. Extrame-
dullary involvement by WM at diagnosis has not been
included in the 5 prognostic factors of ISSWM, and no
report has systematically focused on the treatment of
WM patients who have extramedullary involvement.
The wide use of advanced imaging techniques, such as
positron emission tomography (PET), magnetic resonance
imaging (MRI), and enhanced computed tomography
(CT) has facilitated the evaluation of the extent of involve-
ment by WM and the identification of those WM patients
diagnosed with extramedullary lesion involvement
(EMWM) at time of initial diagnosis. In our clinical
practice, a third of WM patients are diagnosed with
extramedullary involvement at time of diagnosis. No
study has focused systematically on the outcomes of
first-line treatment for patients with EMWM and pa-
tients with only bone marrow involvement (BMWM).
We report our experience regarding the clinical mani-
festations and biological features of WM associated
with EM involvement, as well as the effect of first-line
therapy on patient outcomes, in a large population of
patients at our institution.
Results
Clinical characteristics of patients of WM
A total of 312 patients with WM were identified, with a
median age of 62 years (range, 28–87 years) and a male
to female ratio of 1.2:1. The ethnic distribution of caseswas: 278 white, 14 Hispanic, 13 African-American, and 7
Asian. Eighty-five (27.2 %) patients had B symptoms, 35
(11 %) had neuropathy, 32 (10.3 %) had visual problems,
and 25 (8 %) had amyloidosis. According to the
IPSSWM, 104 (33.3 %) patients were categorized in the
low-risk group (IPSSWM I), 117 (37.5 %) patients in the
medium-risk group (IPSSWM II), and 91 (29.2 %) pa-
tients in the high-risk group (IPSSWM III). A total of
240 symptomatic patients, who were previously un-
treated, received therapeutic agents for WM, including
alkylating agents (chlorambucil, melphalan, and cyclo-
phosphamide), nucleoside analogs (fludarabine, cladri-
bine), rituximab, alone or combinations of these drugs,
and more recently, thalidomide-based regimens, borte-
zomib, and bendamustine. The remainder of the cohort
included 52 patients who were observed (watchful wait-
ing), 11 patients treated in other ways like having Chinese
herbs, X only received radiotherapy, and 9 patients either
refused treatment or detailed treatment information was
not available. With a median follow-up of 66 months
(range, 1–292 months), the 5-year estimates of overall sur-
vival (OS) and progression-free survival (PFS) were 84 and
49 %, respectively, for all WM patients. Using univariate
analysis, we found that factors associated with shorter
median OS included: age over 65 years at diagnosis, B
symptoms, PLT count <100 × 109/L, LDH >618 IU/L,
β2-MG >3 mg/L, albumin (ALB) <3.5 g/dL, and extra-
medullary involvement (P1 = 0.002, P2 = 0.001, P3 = 0.030,
P4 = 0.070, P5 = 0.001, P6 < 0.001, P7 = 0.001).
Immunophenotypic and cytogenetic findings
Consistent with the WHO classification of WM, most of
the immunophenotypic profiles of the WM were negative
for CD5, CD10, and CD23 and were positive for CD20,
CD19, IgM, and monotypic surface immunoglobulin light
chain (k-predominant, 95.2 %). Variable expression of
CD5, CD10, and CD23 was found in a subset of patients
(CD5+ 8.9 %, CD10+ 1.8 %, CD23+ 1.8 %). Conventional
cytogenetic analysis data were available for 261 patients.
An abnormal karyotype was observed in 88 (33.7 %) pa-
tients. Fourteen patients had isolated loss of the Y
chromosome, 37 patients had another single chromosomal
abnormality, 22 patients had a complex karyotype (≥3
abnormalities), and the remaining 15 patients had 2
miscellaneous abnormalities. Deletion of 6q was found
in 18 patients (deletion was isolated in 3 patients, ac-
companied by 1 additional abnormality in 4 patients,
and was part of a complex karyotype in 11 patients).
Extramedullary presentation and pathologic pattern of
EMWM at diagnosis
A total of 106 patients were confirmed as having EMWM
at time of diagnosis, with a median follow-up time of
63 months; 67 patients (63.4 %) were male while 39
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tients were less than 65 years old (Fig. 1b), and lymph
nodes in the abdomen were the most common extrame-
dullary site (n = 71). Other extramedullary sites included
axillary or mediastinal lymph nodes (n = 34), head/neck
lymph nodes (n = 24), spleen (n = 23), pleura (n = 13), ab-
dominal mass (n = 8), kidney (n = 5), liver (n = 2), central
nervous system (n = 2), muscle (n = 2), orbital soft tissue
(n = 1), maxillary sinus (n = 1), and adipose tissue (n = 1).
Bone marrow involvement of these patients was interstitial
in most cases (56 %) (Fig. 1c). The tissue or bone marrow
involvement pattern and immunophenotypic profiling of
representative EMWM and BMWM patients are shown in
Fig. 2. Regardless of BMWM and EMWM, the neoplastic
cells commonly exhibit a diffuse infiltrative pattern and
are mainly composed of abnormal small lymphoid cells



























Fig. 1 Baseline characteristics of patients diagnosed with Waldenström ma
WM. b Age distribution of EMWM patients and BMWM patients. c Patholog(Fig. 2a–c, i–j). They are negative for CD5, CD10, and
CD23 but with strong monotypic immunoglobulin light
chain expression (Fig. 2o).
Different clinical characteristics and survival pattern of
EMWM and BMWM group
Table 1 compares the baseline clinical characteristics of
patients with EMWM and those with BMWM. Of the
EMWM patients (n = 106), 67 (63.2 %) were men and 39
(36.8 %) were women. The sex and age pattern of the
EMWM and BMWM groups are shown in Fig. 1a, b.
The abdomen was the most common site of lymph node
infiltration in the EMWM group (n = 71). The EMWM
group compared with the BMWM group had significantly
more male patients (P = 0.027) and patients younger
than 65 years (P = 0.048); a higher rate of B symptoms
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Fig. 2 The tissue or bone marrow involvement pattern and immunophenotypic profiling of the EMWM and BMWM patients. a, b A representative
diffuse interstitial pattern of bone marrow biopsy in a patient with BMWM, ×40 and × 80 magnification. c Bone marrow aspirate smear showed many
abnormal small lymphoid cells admixed with variable plasmacytoid cells and plasma cells, ×80 magnification. d CD20 stain on the abnormal small
lymphoid cells, ×80 magnification. e CD138 stain on the plasmacytoid and plasma cells, ×80 magnification. f, g Immunophenotypic profiling of CD38
and CD138 positive plasmacytoid and plasma cells with strong monotypic cytoplasmic kappa light chain expression. h The abnormal small lymphoid
cells were CD20 positive and showed monotypic kappa light chain expression. i, j A representative diffuse infiltrative pattern of a lymph node biopsy in
a patient with EMWM, MYD88 mutation positive, ×40 and × 80 magnification. k CD20 stain on abnormal small lymphoid cells, ×80 magnification. l CD138
stain on few admixed plasmacytoid and plasma cells, ×80 magnification.m, o Immunophenotypic profiling of CD19 and CD20 positive small B-cells
with kappa light chain restriction and were negative for CD5 and CD10. p Identical monotypic kappa light chain expression in the lymphoid cells was
also seen in the plasmacytoid and plasma cells
Cao et al. Journal of Hematology & Oncology  (2015) 8:74 Page 4 of 11(P = 0.036); greater rate of increased β2-MG level (P <
0.001); and a higher rate of cytogenetic abnormalities
(P = 0.010). The proportion of IPSSWM III patients was
higher in the EMWM group (36.8 %) than in the
BMWM group (25.2 %), although this difference was
not statistically significant (P = 0.064). The EMWM and
BMWM groups had similar Hb, PLT, IgM, and LDH
levels and a similar percentage of BM involvement. The
tissue or bone marrow involvement pattern and immuno-
phenotypic profiling of the EMWM and BMWM patients
are shown in Fig. 2a-p. Using Kaplan-Meier survival ana-
lysis, the EMWM patients had remarkably shorter median
OS (P < 0.001; Fig. 3a) and PFS (P < 0.001; Fig. 3b) than
did BMWM patients. On univariate analysis, we foundthat age older than 65 years and low ALB level were poor
prognostic factors for EMWM patients (Table 2). Multi-
variate analysis revealed that EMWM patients with low
ALB levels had shorter median OS than EMWM patients
with normal ALB levels. On both univariate and multivari-
ate analysis, EMWM patients with cytogenetic abnormal-
ities had a shorter median OS and PFS than those with a
normal karyotype. The result of multivariate analysis in
the EMWM was different from that of WM patients as a
whole (Table 3).
Outcomes of initial treatments
The general information for the first-line treatment of
WM patients is summarized in Table 4. Eight of the
Table 1 Different clinical manifestations and biological features
between Waldenström macroglobulinemia (WM) patients with
only bone marrow involvement (BMWM) and WM with
extramedullary involvement (EMWM)
Characteristic BMWM EMWM Pa
n (%) n (%)
Age 0.048
≥ 65 years 94 (45.6) 36 (34.0)
< 65 years 112 (54.4) 70 (66.0)
Sex 0.027
Male 103 (50.0) 67 (63.4)
Female 103 (50.0) 39 (36.6)
Hb 0.240
≤ 11.5 (g/dL) 112 (54.4) 65 (61.3)
> 11.5 (g/dL) 94 (45.6) 41 (38.7)
PLT 0.525
≤ 100 (×109/L) 44 (21.4) 26 (24.5)
> 100 (×109/L) 162 (78.6) 80 (75.5)
IgM 0.726
> 70 (g/L) 20 (9.7) 9 (8.5)
≤ 70 (g/L) 186 (90.3) 97 (91.5)
β2-MG <0.001
> 3 (mg/L) 75 (36.4) 71 (64.3)
≤ 3 (mg/L) 131 (63.6) 35 (35.7)
LDH (n = 304) 0.906
> 618 (IU/L) 24 (12.0) 12 (11.5)
≤ 618 (IU/L) 176 (88.0) 92 (88.5)
B symptoms <0.001
Present 41 (19.9) 44 (41.5)
Absent 165 (80.1) 62 (58.5)
ALB (n = 307) 0.036
< 3.5 g/dL 23 (11.3) 21 (20.2)
≥ 3.5 g/dL 180 (88.7) 83 (79.8)
IPSSWM stage 0.064
I 69 (33.5) 35 (33.0)
II 85 (41.3) 32 (30.2)
III 52 (25.2) 39 (36.8)
Cytogenetic findings (n = 261) 0.010
Abnormal 48 (28.2) 40 (44.0)
Normal 122 (71.8) 51 (56.0)
BM involvement 44.52 ± 1.79 46.50 ± 2.49 0.529
(mean ± SD, %)
Hb hemoglobin, PLT platelet, IgM immunoglobulin M, β2-MG beta-2 macroglobulin
level, LDH lactate dehydrogenase, ALB albumin, IPSSWM, International Prognostic
Scoring System for WM
aP value by chi-square and Mann–Whitney U tests; statistically significant
values appear in italics
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to be observed. Another 20 patients were treated with
alternative medicine or radiation, refused treatment, or
did not have detailed treatment information available in
the medical records. These patients were excluded from
the treatment analysis. The treatment analysis thus in-
cluded 240 WM patients who had systemic therapy: 146
BMWM patients and 94 EMWM patients. We first cate-
gorized these 240 patients into the following 3 treatment
groups: (1) chemotherapy group, which included cyto-
toxic drugs such as alkylating agents (chlorambucil and
cyclophosphamide) and nucleoside analogs, NAs (fludar-
abine and cladribine); (2) targeted therapy group, which
included regimens containing the monoclonal antibody
rituximab and the proteasome inhibitor bortezomib,
with or without dexamethasone, but without cytotoxic
chemotherapy; and (3) combination group, which in-
cluded both cytotoxic chemotherapy and biological
agents. The major response rates to first-line therapy (of
any kind) were 90 and 92 % in the EMWM and BMWM
groups, respectively. BMWM patients treated with a
combination of targeted agents and chemotherapy had
significantly longer median PFS (P = 0.004) than did
BMWM patients in the other 2 treatment groups, but
combination treatment had no significant effect on the
EMWM group (Fig. 4a, b). Similar results were shown in
the analysis of patients treated with rituximab and with-
out rituximab. Initial treatment including rituximab im-
proved the PFS of BMWM patients (P = 0.012) (Fig. 4c),
however, there was no difference in the median OS or
PFS on EMWM patients treated with rituximab (Fig. 4d).
We found that EMWM patients treated with NA had
longer median PFS (P = 0.021) than those patients not
treated with NA (P = 0.821), but NA regimens did not
affect PFS significantly in the BMWM group (Fig. 4d, e).
No remarkable differences in OS were observed for the
different treatment groups.
Secondary hematologic neoplasms
During the follow-up period, 11 WM patients developed
secondary hematologic neoplasms: 6 (5.7 %) patients in
the EMWM group, including 2 with myeloproliferative
neoplasms, 1 with plasma cell myeloma, 2 with diffuse
large B-cell lymphoma, and 1 with chronic myelogenous
leukemia; and 5 patients in the BMWM group (2.4 %),
including 2 with chronic myelogenous leukemia, 2 with
diffuse large B-cell lymphoma, and 1 with myeloprolifer-
ative neoplasm.
Discussion
In this study, we have focused on the clinical features
and outcomes of EMWM in a large group of WM pa-
tients. Lymphadenopathy and organomegaly have been
reported in about 20–25 % of patients with WM [6–9].
Fig. 3 Overall survival (OS) and progression-free survival (PFS) of patients. a The Waldenström macroglobulinemia with extramedullary involvement
(EMWM) group had shorter OS than did the WM patients with only bone marrow involvement (BMWM) group. b In the symptomatic WM patients with
standard treatment, the PFS of the EMWM group was also significantly shorter than that of the BMWM group
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logic aspects of extramedullary disease in WM patients
or have excluded some extranodal sites from analysis. In
one study, the authors reported that organomegaly was
associated with a poorer prognosis [7]. Therefore, the
prognostic importance of extramedullary involvement in
WM patients has been inadequately addressed. In recent
years, advances in imaging modalities and the wide use
of these technologies facilitate the detection of EMWM
at diagnosis. This study is the first to evaluate systemat-
ically the manifestations, treatment, and outcome of
extramedullary involvement in WM patients.
Overall, the rate of EMWM at time of diagnosis in this
study was 34 %, a little higher than previous reports withTable 2 Univariate analysis of overall survival (OS) and progression-f
macroglobulinemia (WM) with extramedullary involvement (EMWM)
EMWM
OS PFS
HR 95 % CI Pa HR 95 % CI
Age ≥65 years 1.90 1.02–3.54 0.044 1.04 0.63–1.73
Sex (male) 0.76 0.41–1.39 0.372 0.74 0.45–1.22
Race (white) 0.72 0.29–1.73 0.465 0.54 0.29–1.02
EM-positive - - - - -
IPSSWM (I, II vs III) 1.37 0.95–1.97 0.097 1.08 0.81–1.45
B symptom (+) 1.38 0.75–2.52 0.296 1.05 0.65–1.68
WBC <4 × 1012/L 1.39 0.69–2.82 0.360 1.41 0.80–2.47
Hb ≤11.5 g/L 1.26 0.68–2.34 0.460 0.97 0.59–1.57
PLT <100 × 109/L 1.63 0.88–3.06 0.123 1.37 0.81–2.32
IgM >7000 mg/L 0.24 0.03–1.74 0.158 0.40 0.14–1.10
β2-MG >3 mg/L 1.33 0.68–2.57 0.395 1.15 0.70–1.90
ALB <3.5 g/dL 2.12 1.12–4.00 0.020 1.21 0.69–2.13
LDH >618 IU/L 1.18 0.41–3.37 0.757 1.49 0.75–2.93
Cytogenetic (abnormal) 1.08 0.57–2.03 0.823 1.71 1.03–2.83
BM involvement 0.99 0.97–1.00 0.093 0.99 0.98–1.00
CI confidence interval, HR hazard ratio, EM extramedullary, IPSSWM International Progn
platelet, IgM immunoglobulin M, β2-MG beta-2 microglobulin level, ALB albumin, LDH l
aP value by Cox proportional hazards regression model; statistically significant valueincreased use of PET-CT. Extramedullary disease has
been reported in lymph nodes, the spleen, soft tissue,
and specific organs such as the lungs [10], intestines
[11], and the central nervous system [12]. In this patient
cohort, the most common extramedullary sites were
lymph nodes, especially in the abdomen and pelvis, and
the spleen. Pleural involvement was observed in 12 % of
EMWM patients, and other involved sites included the
central nervous system, soft tissue, liver, kidney, mucosa,
and intestines, most of the sites that have been previ-
ously reported.
The median follow-up for the whole group of WM pa-
tients was 66 months, with 5 year-estimates of OS and
PFS of 84 and 49 %, respectively. EMWM patients had aree survival (PFS) for patients diagnosed with Waldenström
WM
OS PFS
Pa HR 95 % CI Pa HR 95 % CI Pa
0.876 2.09 1.32–3.32 0.002 1.09 0.77–1.56 0.598
0.239 1.06 0.59–1.50 0.799 0.99 0.70–1.39 0.955
0.057 0.66 0.31–1.40 0.281 0.59 0.35–0.98 0.042
- 4.17 2.56–6.79 <0.001 2.38 1.69–3.34 <0.001
0.588 1.85 1.35–2.50 <0.001 1.18 0.96–1.47 0.124
0.842 2.36 1.44–3.85 0.001 1.26 0.88–1.81 0.209
0.234 1.09 0.51–1.65 0.776 1.19 0.79–1.80 0.395
0.886 1.53 0.46–2.45 0.076 0.99 0.70–1.40 0.958
0.243 1.78 1.06–2.99 0.030 1.59 1.08–2.36 0.019
0.075 0.35 0.08–1.43 0.143 0.51 0.26–1.00 0.052
0.598 2.18 1.35–3.50 0.001 1.38 0.98–1.94 0.063
0.501 2.64 1.61–4.35 <0.001 1.53 1.00–2.32 0.049
0.250 1.78 0.95–3.31 0.070 2.02 1.29–3.15 0.002
0.039 1.37 0.83–2.23 0.208 1.77 1.23–2.55 0.002
0.172 1.00 0.99–1.01 0.666 1.00 0.99–1.00 0.417
ostic Scoring System for WM, WBC white blood cell account, Hb hemoglobin, PLT
actate dehydrogenase, BM bone marrow
s appear in italics
Table 3 Multivariate analysis of overall survival (OS) and progression-free survival (PFS) for patients diagnosed with Waldenström
macroglobulinemia (WM) with extramedullary involvement (EMWM)
OS PFS
Variable HR 95 % CI Pa Variable HR 95 % CI Pa
EMWM
Age ≥65 years 1.41 0.67–2.97 0.367 Race (white) 0.50 0.25–1.00 0.051
IPSSWM (I, II vs III) 1.41 0.90–2.21 0.138 IgM >7000 mg/L 0.42 0.15–1.16 0.094
ALB <3.5 g/dL 2.09 1.07–4.07 0.031 Cytogenetic (abnormal) 1.86 1.09–3.17 0.022
BM involvement 0.99 0.98–1.00 0.080 - - - -
WM
Age ≥65 years 3.13 1.85–5.29 <0.001 Race (white) 0.57 0.32–1.05 0.070
Hb ≤11.5 g/L 1.12 0.65–1.93 0.685 IgM >7000 mg/L 0.49 0.23–1.04 0.064
B symptom–positive 1.25 0.72–2.17 0.428 Cytogenetic (abnormal) 1.78 1.21–2.63 0.003
EM–positive 4.28 2.42–7.55 <0.001 EM–positive 2.06 1.39–3.06 <0.001
PLT <100 × 109/L 1.14 0.63–2.05 0.663 PLT <100 × 109/L 0.98 0.60–1.59 0.935
ALB <3.5 g/dL 2.10 1.24–3.54 0.006 ALB <3.5 g/dL 1.12 0.69–1.80 0.648
LDH >618 IU/L 2.00 0.98–4.06 0.054 LDH >618 IU/L 1.47 0.87–2.51 0.153
β2-MG >3 mg/L 1.36 0.78–2.38 0.277 β2-MG >3 mg/L 1.42 0.92–2.17 0.111
CI confidence interval, HR hazard ratio, IPSSWM International Prognostic Scoring System for WM, IgM immunoglobulin M, ALB albumin, BM bone marrow, Hb
hemoglobin, PLT platelet, LDH lactate dehydrogenase, β2-MG beta-2 microglobulin level
aP value by Cox proportional hazards regression model; statistically significant values appear in italics
Table 4 Initial therapy used to treat symptomatic patients
diagnosed with Waldenström macroglobulinemia (WM) with
only bone marrow involvement (BMWM) and those with
extramedullary involvement (EMWM)
Type of therapy EMWM (n = 106) BMWM (n = 206)
n (%) n (%)
Treated for WM
Yes 94 (88.67) 146 (70.87)
Observation only 8 (7.55) 44 (21.36)
Alternative medicine 2 (1.89) 9 (4.37)
Missing data 2 (1.89) 7 (3.40)
Initial treatment
Chemotherapy 20 (18.87) 23 (11.17)
Targeted therapy 25 (23.58) 79 (38.35)
Combination 49 (46.23) 44 (21.36)
Initial treatment with R
Yes 72 (67.92) 118 (57.28)
No 22 (20.75) 28 (13.59)
Initial treatment with NA
Yes 35 (33.02) 61 (29.61)
No 59 (55.67) 85 (41.26)
R rituximab, NA nucleoside analogs
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BMWM patients (Fig. 3). In the univariate analysis of
the whole group, we found that adverse prognostic fac-
tors included age of 65 years or older, B symptoms, PLT
count <100 × 109/L, high LDH levels, high β2-MG levels,
low ALB levels, high ISSWM status, and extramedullary
involvement. Compared with BMWM patients, EMWM
patients had a higher frequency of B symptoms (P < 0.001),
high β2-MG levels (P < 0.001), decreased ALB levels
(P = 0.036), and a higher frequency of cytogenetic abnor-
malities (P = 0.010). All of these factors were confirmed to
be associated with either shorter median OS or PFS on
univariate analysis and also have been reported in previous
studies [13].
Male gender was associated with EMWM, and the age
distribution of EMWM patients was younger than that
of the BMWM patients (P = 0.048). Considering shorter
life expectancy of elderly people and the association be-
tween younger age and extramedullary disease, we sus-
pect that younger than 65 years old is a poor prognostic
factor for WM patients.
EMWM patients were more likely to have stage III
disease than BMWM patients, which is consistent with a
widely accepted international risk stratification system
[14]. Yet, IPSSWM stage was not significantly associated
with a different prognosis for EMWM patients. Whereas
IPSSWM staging showed clear stratification for the
whole WM group, we suspect the reason for this
phenomenon was the interaction of extramedullary in-




Fig. 4 Progression-free survival (PFS) of symptomatic Waldenström macroglobulinemia (WM) patients according to different initial treatments.
a Chemotherapy combined with targeted therapy significantly improved the PFS of patients with WM and only bone marrow involvement
(BMWM) but had no effect on patients diagnosed with WM with extramedullary involvement (EMWM) (b). c BMWM patients who received
treatment with rituximab had better PFS than those treated without rituximab. d Rituximab did not improve PFS in patients with EMWM. e Nucleoside
analogs did not affect the outcome of patients with BMWM but improved the PFS of patients with EMWM (f)
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nostic of WM patients with extramedullary disease
would be valuable.
Cytogenetic studies were conducted in most of the pa-
tients and showed that significantly more EMWM pa-
tients had chromosomal abnormalities than did BMWM
patients (P = 0.010). Additionally, both univariate ana-
lysis and multivariate analysis showed that cytogenetic
abnormalities were associated with shorter median PFS,
consistent with previous report [15]. However, the ab-
normal chromosome result by conventional cytogenetic
analysis was heterogeneous and test for MYD88 or
CXCR4 mutation was not routinely performed in these
patients. Recent studies have shown that CXCR4 muta-
tions and WHIM (warts, hypogammaglobulinemia, infec-
tions, and myelokathexis syndrome) mutations enhance
tumor dissemination and extramedullary involvement
within xenograft mouse models of WM [16, 17]. CXCR4,
a chemokine receptor that regulates cell trafficking anddissemination, may potentially be a factor in the mechan-
ism of extramedullary involvement in patients with WM.
Further studies to detect MYD88 and CXCR4 mutations
and explore new molecular markers in patients with
EMWM may be helpful in clinical practice.
According to current National Comprehensive Cancer
Network recommendations [18], WM patients with symp-
toms related to hyperviscosity syndrome, neuropathy,
organomegaly, amyloidosis, cold agglutinin disease,
cryoglobulinemia, associated cytopenias, and bulky lymph-
adenopathy should be treated. Owing to a lack of consen-
sus on the best treatment for WM patients and to the
availability of new drugs over the period studied, patients
in our study received several types of therapy. Newer
biological agents, such as rituximab and bortezomib,
have been shown to improve the outcome of WM pa-
tients. Consistent with these reports, we found that
BMWM patients treated with both biological agents
and chemotherapy had significantly better median PFS
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logical agents alone, but combination therapy did not
affect PFS in the EMWM group (Fig. 4). The therapeutic
benefit of rituximab for WM has been well documented; it
can be used as single agent or as a combination with other
agents [19, 20]. We also found that BMWM patients
treated with rituximab had significantly longer median
PFS (P = 0.012) and slightly longer median OS (P = 0.064)
than did BMWM patients who were not treated with
rituximab. However, rituximab did not affect survival
in EMWM patients.
Conversely, patients in the EMWM group treated with
nucleoside analog regimens had significantly better PFS
than those not treated with. Nucleoside analogs operate
as antimetabolites by inhibiting DNA synthesis and in-
ducing DNA strand breaks. Earlier studies have showed
that the NAs, fludarabine and cladribine, either alone or
in combination with alkylating agents and rituximab,
produced greater response rates and prolonged survival
in WM patients [21–23]. In a multicenter prospective
study of 43 previously untreated WM patients, the com-
bination of fludarabine, cyclophosphamide, and rituxi-
mab showed a satisfactory overall response rate [24]. On
the other hand, another study reported an increased risk
of disease transformation and the development of mye-
lodysplastic syndrome and secondary acute myelogenous
leukemia in WM patients treated with nucleoside analog
regimens [25]. Per the recommendations of the National
Comprehensive Cancer Network and IWWM-7 [26], the
use of nucleoside analogs in young patients who may be
potential stem cell transplant candidates should be limited.
In this study, 11 WM patients had second hematologic
tumor (6 with EMWM and 5 with BMWM). Of these 11
patients, 5 had been treated with nucleoside analogs; 3 of
these 5 also received alkylating agents. Another 3 patients
had been treated with alkylating agents without nucleoside
analogs. Nine of these 11 patients underwent cytogenetic
analysis and 7 had of chromosome abnormalities. Our
data showed that nucleoside analog regimens did not
affect OS or PFS in the BMWM group, therefore, it is
insufficient to make a conclusion that nucleoside ana-
log use is a risk factor.
Conclusions
In conclusion, our data show that extramedullary in-
volvement at diagnosis is an adverse prognostic factor
for WM patients. EMWM patients treated with nucleo-
side analogs had longer median PFS than did patients
not treated with nucleoside analogs. Given the conflict-
ing reports about the relationship between NA and ma-
lignant transformation risk as well as the limitations of
the IPSSWM in predicting the prognosis of patients with
EMWM, it is helpful to evaluate new prognostic factors,
such as a modified prognostic scoring system or CXCR4mutations to improve the rationale for therapeutic
decisions.
Materials and methods
The data for this study were gathered from the electronic
medical records of patients with WM seen at the Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX,
between 1994 and 2014. Patients without sufficient clinical
data and radiographic were excluded. We retrospectively
analyzed data on patients with EMWM and patients with
bone marrow involvement only (BMWM). Extramedullary
disease was detected by PET, MRI, or enhanced CT scans.
In some patients, the diagnosis was further confirmed by
tissue biopsy. This study was approved by the Institutional
Review Board at the University of Texas MD Anderson
Cancer Center, Houston, TX, in keeping with institutional,
federal, and Helsinki Declaration requirements.
All diagnostic materials were reevaluated for this study
to confirm the WM diagnosis according to the World
Health Organization (WHO) classification of lymphoid
malignancies [2]. All the patients that were diagnosed with
WM have bone marrow involvement with lymphoplasma-
cytoid cell (composed of lymphocytes, plasmacytoid cells,
and plasma cells) and show serum IgM paraprotein of
variable concentration. In addition, they do not fulfill the
criteria for any other B-cell non-Hodgkin lymphomas. To
reach accurate diagnosis for LPL/WM patients in our cen-
ter, series of diagnostic approaches have been used in each
of the patients including BM or tissue biopsy, CT-PET,
molecular and genetic assay, flow cytometry, and import-
antly clinical follow-up of treatment response during the
disease course. Based on the most recent 2016 WHO
Classification Blueprint, MYD88 mutation is present in
greater than 95 % of LPL/WM patients. Molecular and gen-
etic studies including MYD88 mutation have been per-
formed in challenging patients to confirm the diagnosis.
MYD88 mutation has been used routinely in our center for
any possible LPL/WM patients at the current time. As this
study is a retrospective analysis, 9 original and 15 untreated
follow-up LPL/WM patients were analyzed. MYD88 muta-
tion was identified in most of these patients (22/24, 92 %),
which is consistent with reported frequency, supporting
that the original diagnosis and classification are likely accur-
ate in majority of the patients. Baseline data were extracted
from the clinical databases and medical records. Follow-up
information was gathered from each visit record. All pa-
tients were human immunodeficiency virus negative.
We collected the following baseline characteristics: age
and sex; Hb, PLT count, β2-MG, serum IgM, lactate de-
hydrogenase (LDH), albumin (ALB), and cytogenetic re-
sults. Initial treatment records were also obtained. The
IPSSWM score was calculated from these data. Outcomes
of patients were evaluated using the criteria established at
the Second International Workshop on WM (IWWM)
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Because of the typically indolent clinical course of WM,
patients usually had repeated remissions and relapses.
Therefore, we mainly studied patients’ treatment until the
time of first disease progression. For patients who were
switched to a more intensive regimen for reasons other
than progression of disease were categorized into the
group of more intensive regimen for the purposes of this
analysis. Reasons other than disease progression leading to
a change of therapy included unsatisfactory results from
the patient’s perspective, differing opinions of the physi-
cians, or for the purpose of collecting stem cells.
Patient characteristics were summarized using descrip-
tive statistics. Comparisons between two groups were
performed with the chi-square and the Mann–Whitney
tests. PFS was calculated from the date of diagnosis to
the date of first progression, recurrence, or death. OS
was calculated from the date of diagnosis to the date of
death of any cause or the last follow-up date for cen-
sored cases. OS and PFS curves were generated using
the Kaplan-Meier method, and differences between
groups were compared using the log-rank test. Univari-
ate and multivariate analyses were performed with a Cox
proportional hazards regression model. P values less
than 0.05 were considered statistically significant. All
statistical analyses were performed with SPSS software
(version 21.0; IBM, Armonk, NY).
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